NSE: THYROCARE | BSE: 539871

Expensive Performer

Download real time

1011.10 -2.30 (-0.23%)

Near 52W High of ₹1055.00

107.0K NSE+BSE Volume

NSE 28 May, 2025 3:31 PM (IST)

5,358.3

Market Cap

Above industry Median

0.4

Beta 1Year

Very Low volatility

Thyrocare Technologies Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for THYROCARE, BSE:539871 Thyrocare Technologies Ltd.

Search Inside the pdf :

Thyrocare Technologies Ltd.

24 Apr 2025

1011.10

-0.23%

Volume spurt maintained, margin outlook improving

Buy: Thyrocare Technologies Ltd.

Target

ICICI Securities Limited

Thyrocare Technologies’ (Thyrocare) outperformance in Q4FY25 was driven by surge in volumes (up 15%) and realisation improvement, partially offset by higher ESOP cost.

Thyrocare Technologies Ltd. has gained 39.43% in the last 3 Months

Thyrocare Technologies Ltd.

24 Jul 2024

1011.10

-0.23%

Margin thesis is starting to unfold

Buy: Thyrocare Technologies Ltd.

Target

ICICI Securities Limited

Thyrocare Technologies (Thyrocare) has reported a strong 16.4% YoY growth in pathology segment in Q1FY25 in otherwise a seasonally weak quarter.

Thyrocare Technologi.. has an average target of 1000.00 from 1 broker.

Thyrocare Technologies Ltd.

15 May 2024

1011.10

-0.23%

Efforts to improvise volume growth are materialising

Buy: Thyrocare Technologies Ltd.

Recommendation Target

ICICI Securities Limited

Thyrocare Technologies’ (Thyrocare) core business grew 18% YoY in Q4FY24 driven by 13% YoY jump in sales from franchisee and 40% from partnerships (excluding API & B2G). EBITDA margin at 21.9% was weaker (I-Sec: 25.1%) as the company has
inched up investments in marketing and promotion for new bundled test programmes like Jaanch, Her Check and Troponin I and for other initiatives.

Thyrocare Technologi.. has an average target of 1000.00 from 1 broker.

Thyrocare Technologies Ltd.

01 Nov 2023

1011.10

-0.23%

Operations revitalising; mounting debt a concern

Accumulate: Thyrocare Technologies Ltd.

Target

ICICI Securities Limited

Thyrocare’s Q2FY24 performance was in line with our expectations. Its revenue grew 9.7% YoY while the franchisee business grew faster at 20%. It reported an improvement in gross margins (+100bps YoY) due to a decline in the lowmargin Partnership business.

Thyrocare Technologies Ltd. is trading above all available SMAs

Thyrocare Technologies Ltd.

02 Aug 2023

1011.10

-0.23%

Revamping business model to restore margins

Accumulate: Thyrocare Technologies Ltd.

Recommendation Target

ICICI Securities Limited

Thyrocare Technologies has reported an improvement in gross margin (+270bps YoY) in Q1FY24 led by a decline in low margin partnership business. The company has revamped incentive structure offered to franchisees and this should drive a strong 12-14% volume growth in this segment.

Thyrocare Technologies Ltd. is trading above all available SMAs

Thyrocare Technologies Ltd.

14 Nov 2022

1011.10

-0.23%

Limited volume growth hits profitability

Buy: Thyrocare Technologies Ltd.

ICICI Securities Limited

Thyrocare Technologies(Thyrocare) Q2FY23 performance was below our estimates on all fronts. Non-covid pathology revenue grew by 4.6% QoQ, but volumes were flat sequentially.

Thyrocare Technologi.. has an average target of 1000.00 from 1 broker.

Thyrocare Technologies Ltd.

28 Jun 2021, 12:00AM

1011.10

-0.23%

Event Update - Acquisition of THYROCAR to ease PharmEasy's digital offerings - Under Review

Mgmt Note: Thyrocare Technologies Ltd.

Prabhudas Lilladhar

Online pharmacy startup PharmEasy announced acquisition of THYROCARE Technologies, with a view to add diagnostic services in its digital offerings through biochemistry/pathology business. PharmEasy's parent company API...

Thyrocare Technologies Ltd. has gained 39.43% in the last 3 Months

Thyrocare Technologies Ltd.

04 Aug 2020

1011.10

-0.23%

Q1FY21 Result Update - COVID tests continue to impact; Maintain Sell

Sell: Thyrocare Technologies Ltd.

Prabhudas Lilladhar

and 3) increased employee cost at 16% of sales (v/s 11% YoY and 13% QoQ). EBIT margin for diagnostic segment was 9% v/s 42% YoY. its profitability because of 1) lower gross margin at 53% (v/s 72% YoY) due to We remain negative on entire diagnostic chain due to possible structural...

Thyrocare Technologies Ltd. has gained 39.43% in the last 3 Months

Thyrocare Technologies Ltd.

27 May 2020

1011.10

-0.23%

Q4FY20 Result Update - COVID to impact volume growth, profit; Downgrade to Sell

Sell: Thyrocare Technologies Ltd.

Recommendation Target

Prabhudas Lilladhar

Reported lowest ever EBIT margin for diagnostic segment at 25% We reduce our earnings estimate by 56% and 42% for FY21-22E and downgrade THYROCARE to SELL (earlier HOLD) with a new TP of Rs307 (earlier Rs523) 18x PE on FY22E.We believe THYROCARE earnings to be significantly impacted due to 1) loss of core business due to COVID lockdown and low footfall till 1HFY21E 2) post lockdown to struggle for competitive market share 3) high operating expenses (to comply with COVID guidelines).Despite having a track record on asset optimization, EBITDA...

Thyrocare Technologies Ltd. is trading above all available SMAs

Thyrocare Technologies Ltd.

12 Mar 2020

1011.10

-0.23%

Monthly Update - IPM growth not yet impacted by Covid-19

Buy: Thyrocare Technologies Ltd.

Prabhudas Lilladhar

IPM's MAT growth in Feb-20 was 9.7% as against 9.6% in Feb-19 and Jan-20. The growth was majorly contributed by price at 5.4%, volume at 1.9% and new product at 2.5%. In the last 12 months, contributors average growth towards price, volume and new products were 5.6%, 1.7% and 2.3% respectively. The growth attributed by new products and volume however has been on a declining trend in last 50 months, while price hike has been a key factor that has contributed to IPM's growth. With 70-75% intermediaries/API/KSM sourced from China, IPM hasn't been...

Thyrocare Technologies Ltd. has gained 62.98% in the last 1 Year

Is Thyrocare Technologies Ltd. worth buying?

164 Votes:

Buy 76.83%

Sell 12.2%

Hold 10.98%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf